Agilent TechnologiesA

Buy more

Buy more at today's $174, already under our buy price.

5 good· Revenue growth
2 to watch· Fewer buy ratings

$173.54−3.40 (−1.92%)

Price at 3:01 PM ET

After hours · opens in 17h 23m

NYSE · Healthcare · Life Sciences Tools & Services · Large company

Remind me 3 days before earnings

The price we'd buy A at comes with a free account

It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.

What would change it

Sources

Analysts' forecast on the Nasdaq earnings calendar
From the 10-Q for the quarter to Jul 31, reported Aug 26
Yahoo Finance daily closes to Nov 11

Any one could move it to Keep

Next report · Nov 23

below$1.72
earnings per share
Shrinking
sales

Compared with the S&P 500

7 points
worse in one day
15 points
worse in five trading days

+17.0% in a yearsince Nov 11, 2025

Earnings report

The news behind our call

written 10:06 AM ET10:06 AM ET · 1 articles · 1 sources

The panel supports tumor profiling research in hematologic malignancies.
Agilent’s Pan Heme panel broadens its research products.
Agilent’s earnings have grown faster than similar companies.

What changed

From Agilent Technologies via Yahoo Finance, Yahoo Finance, Agilent Technologies via Nasdaq and 2 more

Agilent expanded Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme on Nov 10.

Nov 23

in 11 days

A reports earnings after the market closes

Analysts expect $1.72 a share.

Learn why the bull Case for Agilent stock could Change Following Pan Heme launch
Today
Agilent Technologies (a) expands Tumor Profiling with new Pan Heme Research Panel
Today
Electrophoresis Reagents - Global Strategic business report: Capitalize on China's 7.4% CAGR as Bio-Rad, QIAGEN, Agilent, Merck Millipore and Thermo Fisher Battle for $1.3B by 2032
Tuesday
Agilent expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme
Tuesday
Quant snapshot: Aveanna Healthcare and Fossil lead top-rated names, as KBC Group and DeFi development lag
Sunday
Agilent Technologies' Q4 earnings on Deck: What's in Store for the stock?
Nov 5
Where does Agilent Technologies (a) Value Sit after Proscia?
Nov 4
Microarray Analysis - Global Strategic business report 2026: Secure share in a $5.1 billion market by 2032, Featuring Profiles of key Players Agilent, Illumina, Roche and Thermo Fisher
Nov 4

Overview

In plain numbers

Revenue grew 8.6% from a year earlier, to $7.4B in the last twelve months.
It keeps 25 cents of every revenue dollar as operating profit, up from 22 cents in FY 2021.
It turned 17.2% of revenue into free cash flow: $1.3B in the last twelve months.
It owes $4.1B and holds $1.8B in cash and investments, so net debt is $2.4B.

Key figures

Revenue (TTM): $7.4B
Revenue growth, 1 year: +8.6%
Net income: $1.4B
EPS (diluted): $5.07
Gross margin: 53.6%
Operating margin: 24.5%

Return on equity: 21.0%
Return on capital: 16.9%
Debt / equity: 0.56
Current ratio: 2.05
Dividend yield: 0.59%
Buyback yield: 0.53%

Revenue by region

period ending Sep 30, 2026

Americas$3.0B · 40%
APAC$2.3B · 32%
Europe$2.1B · 28%

Key facts

Company value: $49.3B
Price / last year's earnings: 28.2×
Today's range: 171.26174.62
Past year's range: 109.61181.48

Yesterday's close: $176.95
Swings vs the market: 1.3×about the same
Dividend yield: 0.59%$1.02 a year
Next earnings: Nov 23in 11 days

What would change it

Any one could move it to Keep

Compare A with